Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

RGX-019

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Inspirna, Rockefeller University

Drug class:

MERTK-targeted antibody-drug conjugate

Related drugs:

‹

RGX-019-MMAE (3)

RGX-019-MMAE (3)

›

MERTK expression	Non Small Cell Lung Cancer	MERTK expression	Non Small Cell Lung Cancer	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D
MERTK expression	Breast Cancer	MERTK expression	Breast Cancer	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D
MERTK expression	Melanoma	MERTK expression	Melanoma	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D
MERTK expression	Multiple Myeloma	MERTK expression	Multiple Myeloma	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D
MERTK expression	Triple Negative Breast Cancer	MERTK expression	Triple Negative Breast Cancer	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D
MERTK expression	Acute Myelogenous Leukemia	MERTK expression	Acute Myelogenous Leukemia	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D	RGX-019 Sensitive: D – Preclinical RGX-019 Sensitive : D